Why is Lupin falling/rising?

As of 06-Aug, Lupin Ltd. is experiencing a decline in its stock price, currently at Rs 1,849.00, which reflects a decrease of Rs 14.35 or 0.77%. The stock has been under pressure, having fallen consecutively for the last two days, resulting in a total decline of 1.81%. Although it opened with a gain of 2.5% today and reached an intraday high of Rs 1,910, it remains close to its 52-week low, just 4.06% away. Over the past week, the stock has decreased by 6.77%, while its performance over the last month shows a decline of 6.47%. Despite these short-term challenges, the company has demonstrated healthy long-term growth, with operating profit increasing at an annual rate of 23.59% and a significant rise in net sales.
In the broader market context, Lupin's recent performance contrasts with the benchmark Sensex, which has only declined by 1.15% over the past week. The pharmaceutical sector, in which Lupin operates, has also seen a decrease of 2.06%. While the stock has underperformed relative to the benchmark and sector in the short term, it benefits from a low debt-to-equity ratio and high institutional holdings at 46.82%, indicating strong investor confidence. Additionally, the company’s attractive valuation, evidenced by a PEG ratio of 0.4 and a price-to-book value of 4.9, suggests that it is trading at a discount compared to its peers, which could support future recovery despite current price pressures.